StreetAlpha

CytoSorbents Trades Equity for Debt Relief in $6.25 Million Financing

A $4.0 million direct offering and a lender swap cut debt to $12.25 million and push maturity out to July 2028.

CytoSorbents Trades Equity for Debt Relief in $6.25 Million Financing

Photo by Markus Winkler on Unsplash

CytoSorbents raised $4.0 million in stock and swapped $2.25 million of Avenue debt into equity, cutting total debt to $12.25 million.

The deal on the page

CytoSorbents announced a $6.25 million common stock financing on November 20, priced at the market under Nasdaq rules. The cash piece is a $4.0 million registered direct offering at $4.94 per share, with existing shareholders and management leading. Directors and certain executive officers bought 96,527 shares at $5.18, the consolidated closing bid on November 18. Some investors received pre-funded warrants at $4.939 instead of common shares.

The other $2.25 million is a debt for equity swap. Avenue Capital is receiving 455,465 shares at the same $4.94 price in satisfaction of that much principal. The company also repays $3.0 million of principal in cash, plus a $52,500 prepayment fee and a $270,000 final payment.

The net effect is a $5.25 million reduction in total debt, to $12.25 million. Management puts the interest savings at about $0.7 million over 12 months.

What Avenue gave up, and what it kept

The lender extended maturity by one year to July 1, 2028. The interest only period now runs 15 months longer, through March 31, 2028. For a company still working toward cash flow breakeven, that is the more valuable concession. It pushes principal amortization well past the next two years of operating plans.

Avenue did not leave empty handed. Its old $2.0 million conversion right is replaced by the right to convert up to $3.0 million of principal at $6.916 per share, which is 140% of the offering price. A further $3.125 million can convert at $8.645. Those strikes sit above today's financing level, so the lender is taking a modest equity kicker for the extension and the paydown.

Reading it through the credit lens

Private credit lenders to small cap healthcare have a familiar playbook when a borrower's equity window opens. They take a partial paydown, collect fees, extend the runway and add upside through conversion terms. We saw versions of this through the 2022 and 2023 tightening cycle, when sub $500 million issuers repaired balance sheets by pairing small equity raises with amended loan terms. This deal fits that mold.

The arithmetic deserves a second look. Of the $4.0 million raised, roughly $3.3 million goes straight to Avenue for principal, the prepayment fee and the final payment. That leaves well under $1 million of fresh liquidity before offering costs, by our math. This is balance sheet repair, not a growth raise.

The dilution trade

Equity holders are paying for the lower leverage. Between the offering shares, pre-funded warrants and the shares issued to Avenue, the share count rises meaningfully for a company of this size. The conversion rights add a further overhang if the stock trades through $6.916 and $8.645.

The counterargument is straightforward. Cutting $5.25 million of debt and roughly $0.7 million of annual interest lowers the fixed burden, and insiders buying at $5.18, above the $4.94 institutional price, signals some conviction. Whether that is enough depends on revenue growth and cash burn, which the next quarterly report will show. Traders tracking the name can follow the [CTSO stock page](/stocks/ctso) and the [insider buying](/insider) feed for Form 4 filings tied to this transaction.

What to watch next

The near term questions are mechanical. Watch for the closing of the offering, the resale registration for the Avenue shares and any Form 4 filings from the participating directors and officers. Those will confirm the insider sizing.

Over the next two to four weeks, the broader read is on financing conditions for small cap healthcare. If more issuers in the space can price equity near the market and renegotiate debt terms in the same week, credit access for this cohort is holding up. If deals start requiring warrants or deep discounts, that would point to tighter conditions, and CytoSorbents' at the market pricing would look like the exception.